Fennec Pharmaceuticals Inc.
FENC
$11.29
-$0.06-0.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.16M | 15.11M | 13.78M | 12.46M | 9.65M |
| Total Other Revenue | 710.00K | -- | -- | -- | -- |
| Total Revenue | 17.87M | 15.11M | 13.78M | 12.46M | 9.65M |
| Cost of Revenue | 721.00K | 570.00K | 1.76M | 660.00K | 967.00K |
| Gross Profit | 17.15M | 14.54M | 12.01M | 11.80M | 8.69M |
| SG&A Expenses | 15.30M | 14.61M | 14.55M | 11.96M | 11.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.14M | 15.23M | 16.33M | 12.65M | 12.38M |
| Operating Income | 1.74M | -119.00K | -2.55M | -189.00K | -2.73M |
| Income Before Tax | 2.02M | 201.00K | -4.68M | -638.00K | -3.15M |
| Income Tax Expenses | 42.00K | -- | 106.00K | -- | -- |
| Earnings from Continuing Operations | 1.97M | 201.00K | -4.79M | -638.00K | -3.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.97M | 201.00K | -4.79M | -638.00K | -3.15M |
| EBIT | 1.74M | -119.00K | -2.55M | -189.00K | -2.73M |
| EBITDA | 1.76M | -93.00K | -2.53M | -163.00K | -2.71M |
| EPS Basic | 0.06 | 0.01 | -0.15 | -0.02 | -0.11 |
| Normalized Basic EPS | 0.04 | 0.00 | -0.05 | -0.01 | -0.07 |
| EPS Diluted | 0.05 | 0.01 | -0.15 | -0.02 | -0.11 |
| Normalized Diluted EPS | 0.03 | 0.00 | -0.05 | -0.01 | -0.07 |
| Average Basic Shares Outstanding | 34.55M | 34.34M | 31.18M | 27.89M | 27.66M |
| Average Diluted Shares Outstanding | 36.43M | 35.55M | 31.18M | 27.89M | 27.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |